 Connection
Jane Reusch to Glucagon-Like Peptide-1 Receptor
This is a "connection" page, showing publications Jane Reusch has written about Glucagon-Like Peptide-1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.839 |
|
|
|
-
Scalzo RL, Knaub LA, Hull SE, Keller AC, Hunter K, Walker LA, Reusch JEB. Glucagon-like peptide-1 receptor antagonism impairs basal exercise capacity and vascular adaptation to aerobic exercise training in rats. Physiol Rep. 2018 07; 6(13):e13754.
Score: 0.569
-
Abushamat LA, Reusch JEB. Evolving Concepts of Type 2 Diabetes Management. Med Clin North Am. 2021 Nov; 105(6):955-966.
Score: 0.177
-
Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 2020 Jul; 12(7):488-498.
Score: 0.040
-
Home PD, Ahr?n B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Res Clin Pract. 2017 Sep; 131:49-60.
Score: 0.033
-
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009 Oct; 32(10):1880-6.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|